BR112013003946A2 - uso de diidromiricetina para a preparação de um medicamento a ser administrado a receptores gabaa que serão, são e/ou foram expostos a etanol e uso de diidromiricetina para a preparação de um medicamento a ser adminstrado a recptores gabaa antes, durante e/ou depois da exposição ao etanol . - Google Patents

uso de diidromiricetina para a preparação de um medicamento a ser administrado a receptores gabaa que serão, são e/ou foram expostos a etanol e uso de diidromiricetina para a preparação de um medicamento a ser adminstrado a recptores gabaa antes, durante e/ou depois da exposição ao etanol .

Info

Publication number
BR112013003946A2
BR112013003946A2 BR112013003946A BR112013003946A BR112013003946A2 BR 112013003946 A2 BR112013003946 A2 BR 112013003946A2 BR 112013003946 A BR112013003946 A BR 112013003946A BR 112013003946 A BR112013003946 A BR 112013003946A BR 112013003946 A2 BR112013003946 A2 BR 112013003946A2
Authority
BR
Brazil
Prior art keywords
ethanol
dihydromyretin
administered
drug
exposure
Prior art date
Application number
BR112013003946A
Other languages
English (en)
Portuguese (pt)
Inventor
Igor Spigelman
Jing Liang
Richard W Olsen
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR112013003946A2 publication Critical patent/BR112013003946A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR112013003946A 2010-08-24 2011-08-23 uso de diidromiricetina para a preparação de um medicamento a ser administrado a receptores gabaa que serão, são e/ou foram expostos a etanol e uso de diidromiricetina para a preparação de um medicamento a ser adminstrado a recptores gabaa antes, durante e/ou depois da exposição ao etanol . BR112013003946A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37652810P 2010-08-24 2010-08-24
PCT/US2011/048749 WO2012027326A2 (en) 2010-08-24 2011-08-23 Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin

Publications (1)

Publication Number Publication Date
BR112013003946A2 true BR112013003946A2 (pt) 2016-07-12

Family

ID=45724009

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003946A BR112013003946A2 (pt) 2010-08-24 2011-08-23 uso de diidromiricetina para a preparação de um medicamento a ser administrado a receptores gabaa que serão, são e/ou foram expostos a etanol e uso de diidromiricetina para a preparação de um medicamento a ser adminstrado a recptores gabaa antes, durante e/ou depois da exposição ao etanol .

Country Status (14)

Country Link
US (1) US20130053435A1 (cg-RX-API-DMAC7.html)
EP (1) EP2608786A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013536238A (cg-RX-API-DMAC7.html)
KR (1) KR20130098347A (cg-RX-API-DMAC7.html)
CN (1) CN103269699A (cg-RX-API-DMAC7.html)
AU (1) AU2011293556A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013003946A2 (cg-RX-API-DMAC7.html)
CA (1) CA2808680A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013000518A1 (cg-RX-API-DMAC7.html)
EA (1) EA201390217A1 (cg-RX-API-DMAC7.html)
MX (1) MX2013002162A (cg-RX-API-DMAC7.html)
PH (1) PH12013500293A1 (cg-RX-API-DMAC7.html)
SG (1) SG187771A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012027326A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007853A1 (en) * 2012-07-03 2014-01-09 The Regents Of The University Of California Dihydromyricetin for the treatment of diseases and disorders of the glutamatergic system
CN103772338A (zh) * 2014-01-10 2014-05-07 吉首大学 真空脉动式制备二氢杨梅素的方法
EP3761979A4 (en) * 2018-04-06 2021-06-30 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT SUBSTANCE ABUSE
CN108567772A (zh) * 2018-07-24 2018-09-25 广西师范大学 二氢杨梅素的新用途
EP3876926A1 (de) * 2018-11-05 2021-09-15 Evanium Healthcare GmbH Alkohol-antidot
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
TW202110437A (zh) * 2019-05-23 2021-03-16 美商希諾瓦有限責任公司 用於酒精誘發之皮膚潮紅之治療及緩解的組成物及方法
MX2021015457A (es) 2019-06-14 2022-04-06 Univ Princeton Formulaciones de dihidromiricetina y un permeabilizante.
GR1010117B (el) 2020-07-14 2021-11-08 Uni Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Διατροφικο συμπληρωμα για την απο του στοματος χορηγηση συνδυασμου διυδρομυρισετινης, χολινης και μιας ή περισσοτερων βιταμινων με αντιοξειδωτικη δραση, χρησιμων για τη φυσιολογικη λειτουργια του ηπατος
CN112546014B (zh) * 2020-12-15 2023-01-31 铜仁职业技术学院 一种中药解酒护肝泡腾片及其制备方法
CN118354770A (zh) * 2021-10-07 2024-07-16 罗特格斯新泽西州立大学 具有gabaa受体活性的类黄酮衍生物及使用方法
CN113842461B (zh) * 2021-11-04 2023-08-11 杭州诺莘科技有限责任公司 用于缓解、治疗酒精中毒、酒后不适的gabaa受体结合物、组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1293825C (zh) * 2002-08-30 2007-01-10 广州拜迪生物医药有限公司 二氢杨梅树皮素在制备食品、化妆品或药品中的应用
KR20040021927A (ko) * 2002-09-06 2004-03-11 차재영 호깨나무와 홍삼 추출물을 이용한 건강 보조식품프로헤파-알지의 개발
CN101336978B (zh) * 2008-08-12 2013-01-30 西北农林科技大学 一种北枳椇总黄酮的提取方法
CN101336987B (zh) * 2008-08-12 2012-04-25 西北农林科技大学 一种枳椇总黄酮的制备方法

Also Published As

Publication number Publication date
MX2013002162A (es) 2013-04-05
PH12013500293A1 (en) 2013-03-25
CA2808680A1 (en) 2012-03-01
KR20130098347A (ko) 2013-09-04
WO2012027326A9 (en) 2012-04-19
EA201390217A1 (ru) 2013-12-30
US20130053435A1 (en) 2013-02-28
EP2608786A2 (en) 2013-07-03
AU2011293556A1 (en) 2013-02-28
SG187771A1 (en) 2013-03-28
CN103269699A (zh) 2013-08-28
JP2013536238A (ja) 2013-09-19
CL2013000518A1 (es) 2013-08-02
WO2012027326A2 (en) 2012-03-01
EP2608786A4 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
CL2013001713A1 (es) Compuestos derivados de bemzimidazol, proceso para prepar dichos compuestos; composicion farmaceutica que los comprende; proceso para preparar esta composicion farmaceutica; y su uso para inhibir la replicacion del visus sincicial respiratorio (rsv).
CL2008000022A1 (es) Compuestos derivados de fenil-(4-fenil pirimidin-2-il)-aminas; composicion farmaceutica que comprende a dichos compuestos ; procedimiento de preparacion de dichos compuestos; y su uso en enfermedades inflamatorias, diabetes y cancer.
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
CL2008000703A1 (es) Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos.
CL2013001885A1 (es) Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
BR112013023174A2 (pt) "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos"
BR112013016761A2 (pt) uso de um composto, composto da fórmula, composição farmacêutica, oligonucleotídeo, conjugado de molécula pequena e um oligonucleotídeo, compostos, uso e métodos
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
EP2827866A4 (en) PHARMACEUTICAL COMPOSITIONS WITH BENZYL ALCOHOL
CL2007003082A1 (es) Compuestos derivados de dihidropirazolonas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiocirculatorias, insuficiencia cardiaca, anemia, enfermedad renal cronica e in
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
CL2008002726A1 (es) Compuestos derivados de isoquinolinilo e isoindolinilo, antagonistas de histamina-3; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos del sistema nervioso c
BRPI0911019A2 (pt) "composição farmacêutica, especialidade farmacêutica, progesterona micronizada em óleo de cártamo de tipo ii e uso da progesterona micronizada em cártamo óleo de tipo ii"
CO6920294A2 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
UY31922A (es) Compuestos
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
CL2013000734A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.
CL2008001048A1 (es) Compuestos derivados de heterociclos nitrogenados; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como antibacterianos.
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
BRPI0916571A2 (pt) composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto
UY33274A (es) Proteínas de unión a basigina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.